Abstract
Molecular Responses Are Observed across Mutational Spectrum in Treatment-Naïve Higher-Risk Myelodysplastic Syndrome Patients Treated with Venetoclax Plus Azacitidine
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have